Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

erevnon Mar. 2 at 6:16 PM

Goldman Sachs maintains Celldex Therapeutics $CLDX at Neutral and raises the price target from $30 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StockNews_Live Mar. 1 at 2:46 PM

$CLDX Celldex presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after sym…

0 · Reply

lucabrix Feb. 28 at 8:53 PM

$CLDX Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory By Ricardo Pillai | February 28, 2026, 1:26 PM Celldex Therapeutics Inc. (CLDX) is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. The company has initiated a second Phase III/registration trial for its lead compound, barzolvolimab (“barzo”), in chronic inducible urticaria (CIndU), mirroring its successful Phase III chronic spontaneous urticaria (CSU) design and incorporating a booster initial dose to enhance early efficacy, a well-established practice for injectable monoclonal antibodies. Barzo is uniquely positioned as a “pipeline in a drug,” targeting multiple mast cell diseases and commanding potential premium pricing.

0 · Reply

StockNews_Live Feb. 27 at 7:45 PM

$CLDX Celldex presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (…

0 · Reply

lucabrix Feb. 26 at 8:51 PM

$CLDX holding well with new high

0 · Reply

erevnon Feb. 26 at 2:55 PM

Stifel reiterates Celldex Therapeutics $CLDX at Buy and raises the price target from $58 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Feb. 26 at 4:36 AM

$CLDX RSI: 72.26, MACD: 0.0657 Vol: 1.71, MA20: 24.38, MA50: 25.60 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

mikesterz7 Feb. 26 at 3:43 AM

$CLDX The company now expects data from the program in the fourth quarter of 2026. The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027.

0 · Reply

tommy_john Feb. 26 at 12:33 AM

$CLDX major breakout. Can keep grinding higher now

0 · Reply

Timefortendies77 Feb. 26 at 12:25 AM

$CLDX After this pop what do we have to keep going besides the Q4 results coming that will change the GAME!

0 · Reply

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Feb 25, 2026, 4:01 PM EST - 5 days ago

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Feb 25, 2026, 7:01 AM EST - 6 days ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb 23, 2026, 8:01 AM EST - 8 days ago

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb 9, 2026, 8:01 AM EST - 22 days ago

Celldex to Present at Upcoming Investor Conferences

Jan 13, 2026, 3:20 PM EST - 6 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 3

CEG COST CRNT DOCN DX

Dec 9, 2025, 8:01 AM EST - 3 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Nov 10, 2025, 8:01 AM EST - 4 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Sep 17, 2025, 5:11 AM EDT - 5 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 10, 2025, 12:20 PM EDT - 6 months ago

Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 9:01 AM EDT - 6 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 21, 2025, 3:45 PM EDT - 6 months ago

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track

Aug 20, 2025, 10:22 AM EDT - 6 months ago

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Aug 19, 2025, 4:01 PM EDT - 6 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 14, 2025, 10:48 AM EDT - 9 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 9 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 10, 2025, 4:01 PM EDT - 9 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 9 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 10 months ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:01 PM EDT - 10 months ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Mar 4, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 3:14 PM EST - 1 year ago

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 1 year ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth

May 6, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 17, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Mar 5, 2024, 10:10 AM EST - 2 years ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 29, 2024, 9:14 PM EST - 2 years ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 2 years ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 2 years ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 24, 2024, 2:05 PM EST - 2 years ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 2 years ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

erevnon Mar. 2 at 6:16 PM

Goldman Sachs maintains Celldex Therapeutics $CLDX at Neutral and raises the price target from $30 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StockNews_Live Mar. 1 at 2:46 PM

0 · Reply

lucabrix Feb. 28 at 8:53 PM

0 · Reply

StockNews_Live Feb. 27 at 7:45 PM

0 · Reply

lucabrix Feb. 26 at 8:51 PM

$CLDX holding well with new high

0 · Reply

erevnon Feb. 26 at 2:55 PM

Stifel reiterates Celldex Therapeutics $CLDX at Buy and raises the price target from $58 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Feb. 26 at 4:36 AM

0 · Reply

mikesterz7 Feb. 26 at 3:43 AM

0 · Reply

tommy_john Feb. 26 at 12:33 AM

$CLDX major breakout. Can keep grinding higher now

0 · Reply

Timefortendies77 Feb. 26 at 12:25 AM

$CLDX After this pop what do we have to keep going besides the Q4 results coming that will change the GAME!

0 · Reply

StocktwitsNews Feb. 26 at 12:05 AM

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent $CLDX $VTI $XBI https://stocktwits.com/news/equity/markets/cldx-soars-on-bullish-timelines-for-urticaria-clinical-program/cZR6sBHRIGw

0 · Reply

Sw1ngb0t Feb. 25 at 9:27 PM

$CLDX $37.18+

0 · Reply

free2dream Feb. 25 at 8:40 PM

$CLDX Ciiti has $70 target and thats too low, you take dupixent salesat $20B annually , $CLDX Barzo will be 3x that . This could easily be $25B company

1 · Reply

junov239 Feb. 25 at 8:38 PM

$CLDX offering ?

1 · Reply

InfernoDrake Feb. 25 at 8:27 PM

$OPEN $PSTV $CLDX $BDMD ^^

0 · Reply

DragonForce1 Feb. 25 at 7:51 PM

$KOS $HIND $NXL $CLDX =

0 · Reply

InfernoDrake Feb. 25 at 7:08 PM

$ACHC $CLDX $AGL $ASST ~

0 · Reply

Wolfofwannabe Feb. 25 at 5:52 PM

$CLDX

0 · Reply

free2dream Feb. 25 at 5:41 PM

$CLDX one of the most undiscovered and ignored biotech in the entire market. Barzolvolimab will be larger than dupixent which ahs $20B annual sales. Everyone still chases the hyped up toxic AI garbage like $SNDK $MU $LITE

1 · Reply

lucabrix Feb. 25 at 3:59 PM

$CLDX 200$ I said and so will be!

0 · Reply

MaverikIT Feb. 25 at 3:19 PM

$CLDX nice

0 · Reply

Wolfofwannabe Feb. 25 at 2:46 PM

$CLDX wowza !

0 · Reply

Market Cap	2.00B
Revenue (ttm)	7.02M
Net Income (ttm)	-157.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,248.72%
Debt to Equity Ratio	0.00

Volume	668,718
Avg Vol	786,842
Day's Range	N/A - N/A
Shares Out	66.57M
Stochastic %K	85%
Beta	1.24
Analysts	Strong Sell
Price Target	$56.08